Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
49
ESAIY Quote, Financials, Valuation and Earnings
Last price:
$7.14
Seasonality move
:
-4.11%
Day range:
$7.14 - $7.18
52-week range:
$5.94 - $9.22
Dividend yield:
0%
P/E ratio:
24.31x
P/S ratio:
1.49x
P/B ratio:
1.39x
Volume:
71.4K
Avg. volume:
126.7K
1-year change:
4.54%
Market cap:
$8.1B
Revenue:
$5.2B
EPS (TTM):
$0.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESAIY
Eisai Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7B | -- | 3.35% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESAIY
Eisai Co., Ltd.
|
$7.14 | -- | $8.1B | 24.31x | $0.14 | 0% | 1.49x |
|
HLOSF
Healios KK
|
$2.31 | -- | $266.6M | -- | $0.00 | 0% | 362.71x |
|
PPTDF
PeptiDream Inc.
|
$12.80 | -- | $1.7B | 13.79x | $0.00 | 0% | 13.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.34 | -- | $483.2M | -- | $0.00 | 0% | 2.50x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.90 | $17.93 | $47.1B | 189.09x | $0.32 | 4.44% | 1.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESAIY
Eisai Co., Ltd.
|
21.69% | 0.737 | 16.39% | 1.39x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESAIY
Eisai Co., Ltd.
|
$1B | $76.2M | 4.65% | 5.83% | 5.7% | $151.8M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Eisai Co., Ltd. vs. Competitors
-
Which has Higher Returns ESAIY or HLOSF?
Healios KK has a net margin of 5.34% compared to Eisai Co., Ltd.'s net margin of -9751.87%. Eisai Co., Ltd.'s return on equity of 5.83% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital ESAIYEisai Co., Ltd.76.93% $0.06 $7.6B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About ESAIY or HLOSF?
Eisai Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai Co., Ltd. has higher upside potential than Healios KK, analysts believe Eisai Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings ESAIYEisai Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is ESAIY or HLOSF More Risky?
Eisai Co., Ltd. has a beta of 0.404, which suggesting that the stock is 59.576% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock ESAIY or HLOSF?
Eisai Co., Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai Co., Ltd. pays 59.57% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Eisai Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESAIY or HLOSF?
Eisai Co., Ltd. quarterly revenues are $1.3B, which are larger than Healios KK quarterly revenues of $128.8K. Eisai Co., Ltd.'s net income of $71.4M is higher than Healios KK's net income of $3.8M. Notably, Eisai Co., Ltd.'s price-to-earnings ratio is 24.31x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai Co., Ltd. is 1.49x versus 362.71x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESAIYEisai Co., Ltd.1.49x 24.31x $1.3B $71.4M HLOSFHealios KK362.71x -- $128.8K $3.8M
-
Which has Higher Returns ESAIY or PPTDF?
PeptiDream Inc. has a net margin of 5.34% compared to Eisai Co., Ltd.'s net margin of -25.38%. Eisai Co., Ltd.'s return on equity of 5.83% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital ESAIYEisai Co., Ltd.76.93% $0.06 $7.6B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About ESAIY or PPTDF?
Eisai Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Eisai Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESAIYEisai Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is ESAIY or PPTDF More Risky?
Eisai Co., Ltd. has a beta of 0.404, which suggesting that the stock is 59.576% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock ESAIY or PPTDF?
Eisai Co., Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai Co., Ltd. pays 59.57% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Eisai Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESAIY or PPTDF?
Eisai Co., Ltd. quarterly revenues are $1.3B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Eisai Co., Ltd.'s net income of $71.4M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Eisai Co., Ltd.'s price-to-earnings ratio is 24.31x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai Co., Ltd. is 1.49x versus 13.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESAIYEisai Co., Ltd.1.49x 24.31x $1.3B $71.4M PPTDFPeptiDream Inc.13.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns ESAIY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 5.34% compared to Eisai Co., Ltd.'s net margin of -24.76%. Eisai Co., Ltd.'s return on equity of 5.83% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital ESAIYEisai Co., Ltd.76.93% $0.06 $7.6B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About ESAIY or SOLTF?
Eisai Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Eisai Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ESAIYEisai Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is ESAIY or SOLTF More Risky?
Eisai Co., Ltd. has a beta of 0.404, which suggesting that the stock is 59.576% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock ESAIY or SOLTF?
Eisai Co., Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai Co., Ltd. pays 59.57% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Eisai Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESAIY or SOLTF?
Eisai Co., Ltd. quarterly revenues are $1.3B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Eisai Co., Ltd.'s net income of $71.4M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Eisai Co., Ltd.'s price-to-earnings ratio is 24.31x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai Co., Ltd. is 1.49x versus 2.50x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESAIYEisai Co., Ltd.1.49x 24.31x $1.3B $71.4M SOLTFNxera Pharma Co., Ltd.2.50x -- $45.8M -$11.3M
-
Which has Higher Returns ESAIY or STMM?
Stemcell Holdings, Inc. has a net margin of 5.34% compared to Eisai Co., Ltd.'s net margin of --. Eisai Co., Ltd.'s return on equity of 5.83% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESAIYEisai Co., Ltd.76.93% $0.06 $7.6B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About ESAIY or STMM?
Eisai Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Eisai Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESAIYEisai Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is ESAIY or STMM More Risky?
Eisai Co., Ltd. has a beta of 0.404, which suggesting that the stock is 59.576% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ESAIY or STMM?
Eisai Co., Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai Co., Ltd. pays 59.57% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Eisai Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ESAIY or STMM?
Eisai Co., Ltd. quarterly revenues are $1.3B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Eisai Co., Ltd.'s net income of $71.4M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Eisai Co., Ltd.'s price-to-earnings ratio is 24.31x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai Co., Ltd. is 1.49x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESAIYEisai Co., Ltd.1.49x 24.31x $1.3B $71.4M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns ESAIY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 5.34% compared to Eisai Co., Ltd.'s net margin of -1.05%. Eisai Co., Ltd.'s return on equity of 5.83% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital ESAIYEisai Co., Ltd.76.93% $0.06 $7.6B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About ESAIY or TAK?
Eisai Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 20.32%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Eisai Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Eisai Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ESAIYEisai Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is ESAIY or TAK More Risky?
Eisai Co., Ltd. has a beta of 0.404, which suggesting that the stock is 59.576% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock ESAIY or TAK?
Eisai Co., Ltd. has a quarterly dividend of $0.14 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.44% to investors and pays a quarterly dividend of $0.32 per share. Eisai Co., Ltd. pays 59.57% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Eisai Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios ESAIY or TAK?
Eisai Co., Ltd. quarterly revenues are $1.3B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Eisai Co., Ltd.'s net income of $71.4M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Eisai Co., Ltd.'s price-to-earnings ratio is 24.31x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 189.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai Co., Ltd. is 1.49x versus 1.60x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESAIYEisai Co., Ltd.1.49x 24.31x $1.3B $71.4M TAKTakeda Pharmaceutical Co., Ltd.1.60x 189.09x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
